ClinicalTrials.gg
CompletedNCT00152516Updated Feb 12, 2013Results posted

Long-Term, Follow-Up Study Of the Safety And Efficacy Of Levetiracetam In Children With Partial Onset Seizures

A Phase 3 interventional study of levetiracetam (LEV) in Epilepsy, Partial, sponsored by UCB Pharma. Completed at 85 sites in 16 countries. Open to participants aged 1 Month to 16 Years. Per ClinicalTrials.gov, last updated 2013-02-12.

Sponsored by UCB Pharma (part of UCB S.A.) · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
255
Allocation
Non-randomized
Ages
1 Month to 16 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 18 studies testing levetiracetam in Epilepsies, Partial — none open to participants now, none under way, none of them phase 3. Levetiracetam · Epilepsies, Partial.

Enrollment
6th of 18
255 · median 173
Started
2004
with 4 others
Phase 3
10 of 18
none open now
Registered
3rd of 18
by date
Lead sponsor
10 of 18
UCB Pharma

Among the 18 studies testing levetiracetam in Epilepsies, Partial, this one is the 6th largest by enrollment, is one of 5 that started in 2004, is one of 10 in phase 3, and was the 3rd registered.

Epilepsies, Partial

243 studies on the registry are indexed under Epilepsies, Partial; 49 are open to participants now.

Browse Epilepsies, Partial studies →

Open to participants now

None of the 18 studies testing levetiracetam in Epilepsies, Partial is open now. The open studies under Epilepsies, Partial, anywhere →

About levetiracetam

Levetiracetam: first FDA approval 1999 (KEPPRA), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 37 Epilepsies, Partial studies recruiting now, 9 (24%) set no upper age limit and 24 (65%) stop at 75 or younger; 17 take children under 18; 3 take healthy volunteers.

This study: 1 Month to 16 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies testing levetiracetam in Epilepsies, Partial as a file.
02

Study summary

To allow pediatric patients with partial onset seizures an opportunity to receive (as follow-up to studies N01009(NCT00105040)/N01103(NCT00175890) or by direct enrollment) open-label levetiracetam treatment, continue studying cognition and behavior in children, and continue collection of safety/efficacy data.

03

Conditions studied

  • Epilepsy, Partial

Keywords

  • Partial Onset Seizures
  • levetiracetam
  • Epilepsy
  • Keppra
04

Who can participate

Ages eligible
1 Month to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pediatric patients with partial onset seizures, with 1 to 2 anti-epileptic drugs (AEDS), with participation in previous levetiracetam pediatric studies (N01009 or N01103) or direct enrollment, for whom levetiracetam treatment will be of possible benefit

Exclusion criteria

Exclusion Criteria:

  • Patients on a ketogenic diet
  • Seizures too close together to accurately count
  • Pseudoseizures
  • Status epilepticus 1 month prior Visit 1
  • Current diagnosis of Lennox-Gastaut Syndrome or epilepsy secondary to a progressing cerebral disease will be excluded from the study.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
255 participants (actual)

Study arms

  • Experimental
    Levetiracetam

    Drug: levetiracetam (LEV)

Interventions

  • DrugLevetiracetamStudies of LevetiracetamLevetiracetam pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Per protocol oral tablets or oral solution at 10 to 30mg/kg/day bid for 48 weeks, or approximately 52 weeks should a subject choose to discontinue levetiracetam (LEV) at the end of the maintenance period.

    Also known as: Keppra

06

What researchers measure

Primary outcomes

  1. Percentage Change (Reduction) of Partial (Type I) Seizure Frequency Per Week From Baseline Over Time During Treatment Period.

    Positive changes from Baseline indicate an improvement (i.e., a reduction) in seizure frequency per week.

    Time frame: Up-titration/Conversion Period (2-8 weeks); Maintenance Period (2-8 weeks to 40-46 weeks)

Secondary outcomes

  1. Percentage Change (Reduction) of Total (Type I, II, III) Seizure Frequency Per Week From Baseline Over Time During Treatment Period.

    Positive changes from Baseline indicate an improvement (i.e., a reduction) in seizure frequency per week.

    Time frame: Up-titration/Conversion Period (2-8 weeks); Maintenance Period (2-8 weeks to 40-46 weeks)

  2. Partial (Type I) Seizure Frequency Per Week Over Time During Treatment Period.

    Time frame: Up-titration/Conversion Period (2-8 weeks); Maintenance Period (2-8 weeks to 40-46 weeks)

  3. Total (Type I, II, III) Seizure Frequency Per Week Over Time During Treatment Period.

    Time frame: Up-titration/Conversion Period (2-8 weeks); Maintenance Period (2-8 weeks to 40-46 weeks)

  4. Change (Reduction) From Baseline in Partial (Type I) Seizure Frequency Per Week Over Time During Treatment Period

    Positive changes from Baseline indicate an improvement (i.e., a reduction) in seizure frequency per week.

    Time frame: Up-titration/Conversion Period (2-8 weeks); Maintenance Period (2-8 weeks to 40-46 weeks)

  5. Change (Reduction) From Baseline in Total (Type I, II, III) Seizure Frequency Per Week Over Time During Treatment Period

    Positive changes from Baseline indicate an improvement (i.e., a reduction) in seizure frequency per week.

    Time frame: Up-titration/Conversion Period (2-8 weeks); Maintenance Period (2-8 weeks to 40-46 weeks)

  6. Partial Seizure (Type I) Responder Rate (Percent) During the Up-titration/Conversion Phase and by Visit During the Maintenance Phase

    The responder rate is defined as the number of responders. A responder is a patient with a 50% or greater change (reduction) in partial seizure frequency per week. Note: Rates were reported as percentages.

    Time frame: Up-titration (4 weeks); Maintenance Visits 3-4 (weeks 4-14, 6-15, or 8-16); Visits 4-5 (weeks 14-24, 15-24, or 16-24); Visits 5-6 (weeks 24-36); Visits 6-7 (weeks 36-48)

  7. Partial Seizure (Type I) Maximum Seizure Free Interval (Percentage of Days Belonging to a Seizure Free Interval of 28 Days or More)

    For subjects with up to 24 weeks in the evaluation phase the denominator for each subject is their number of days in the evaluation phase.

    Time frame: Subjects with up to 24 weeks of exposure

  8. Partial Seizure (Type I) Maximum Seizure Free Interval (Percentage of Days Belonging to a Seizure Free Interval of 28 Days or More)

    For subjects with greater than 24 weeks in the evaluation phase the denominator for each subject is their number of days in the evaluation phase.

    Time frame: Subjects with greater than 24 weeks of exposure

  9. Total Seizure (Type I, II, III) Maximum Seizure Free Interval (Percentage of Days Belonging to a Seizure Free Interval of 28 Days or More)

    For subjects with up to 24 weeks in the evaluation phase the denominator for each subject is their number of days in the evaluation phase.

    Time frame: Subjects with up to 24 weeks of exposure

  10. Total Seizure (Type I, II, III) Maximum Seizure Free Interval (Percentage of Days Belonging to a Seizure Free Interval of 28 Days or More)

    For subjects with greater than 24 weeks in the evaluation phase the denominator for each subject is their number of days in the evaluation phase.

    Time frame: Subjects with greater than 24 weeks of exposure

  11. Total Seizure (Type I, II, III) Continuously Seizure Free During the Maintenance Period

    The measure description is the product limit adjusted percent of subjects seizure free starting from the beginning of the Maintenance Period. The up-titration period is the up to 6 week period of increasing dose prior to the Maintenance Period. The Maintenance Period is the period of stable dosing, subsquent to the up-titration period, which could last from 42 to 48 weeks.

    Time frame: greater than or equal to 24 weeks, greater than or equal to 40 weeks

  12. Percent of Subjects With Each Seizure Type During the Evaluation Period

    Type I Seizure is a partial onset Seizure (see International League Against Epilepsy definitions). Type II Seizure is a Generalized Seizure (see International League Against Epilepsy definitions). Type III Seizure is a Unknown Seizure Type (see International League Against Epilepsy definitions). A subject could experience more than one seizure type.

    Time frame: Evaluation period (48 weeks)

  13. Investigator Global Evaluation Scale

    There are 7 categories, 3 for improvement (Marked improvement, Moderate improvement, Slight improvement), 3 for worsening (Slight worsening, Moderate worsening, Marked worsening), and 1 for no change (No change).

    Time frame: End of Evaluation period (week 48 or at point of early discontinuation)

  14. Parent/Guardian Global Evaluation Scale

    There are 7 categories, 3 for improvement (Marked improvement, Moderate improvement, Slight improvement), 3 for worsening (Slight worsening, Moderate worsening, Marked worsening), and 1 for no change (No change).

    Time frame: End of Evaluation period (week 48 or at point of early discontinuation)

  15. Subject (>=8 Years Old) Global Evaluation Scale

    There are 7 categories, 3 for improvement (Marked improvement, Moderate improvement, Slight improvement), 3 for worsening (Slight worsening, Moderate worsening, Marked worsening), and 1 for no change (No change).

    Time frame: End of Evaluation period (week 48 or at point of early discontinuation)

  16. Leiter-R Associated Memory (AM) Memory Screen Composite Score Change From Baseline to Visit 5 (Week 24) and Visit 7 (Week 48) (4 to 16 Year Olds)

    The Leiter-R AM battery has 10 subtests. The raw scores of the subtests are converted into scaled scores. Six composite scores are constructed from the 10 subtest scaled scores. The Memory Screen is one of them. It is composed of 2 subtests the Associated Pairs and Forward Memory. The sum of the Associated Pairs and Forward Memory subtest scaled scores are converted into a Memory composite score normally distributed with a mean and standard deviation of 100 (±15). Higher scores and positive changes from baseline are better. The range of the Memory Screen composite score is 44 to 155.

    Time frame: Baseline to Visit 5 (Week 24) and Visit 7 (Week 48)

  17. Bayley Scale of Infant Development (BSID) II Mental Development Index Scores Classification Shift From Baseline at Visit 5 (Week 24) (1 Month to < 4 Year Olds)

    This score is obtained from a total raw score which is the sum of a battery of individual questions. It is adjusted for a child's age, has an expected mean of 100 and standard deviation of 15, and can be categorized as: (1) Accelerated Performance (\>= 115), (2) Within Normal Limits (85-114), (3) Mildly Delayed Performance (70-84), and (4) Significantly Delayed Performance (\<=69). Changes from baseline are then further categorized where 'Improved' is any positive category change, 'Stable' is no category change, and 'Worsened' is any negative category change, from baseline.

    Time frame: Visit 5 (Week 24)

  18. Bayley Scale of Infant Development (BSID) II Mental Development Index Scores Classification Shift From Baseline at Visit 7 (Week 48) (1 Month to < 4 Year Olds)

    This score is obtained from a total raw score which is the sum of a battery of individual questions. It is adjusted for a child's age, has an expected mean of 100 and standard deviation of 15, and can be categorized as: (1) Accelerated Performance (\>= 115), (2) Within Normal Limits (85-114), (3) Mildly Delayed Performance (70-84), and (4) Significantly Delayed Performance (\<=69). Changes from baseline are then further categorized where 'Improved' is any positive category change, 'Stable' is no category change, and 'Worsened' is any negative category change, from baseline.

    Time frame: Visit 7 (week 48)

  19. Bayley Scale of Infant Development (BSID) II Psychomotor Development Index Scores Classification Shift From Baseline at Visit 5 (Week 24) (1 Month to < 4 Year Old)

    This score is obtained from a total raw score which is the sum of a battery of individual questions. It is adjusted for a child's age, has an expected mean of 100 and standard deviation of 15, and can be categorized as: (1) Accelerated Performance (\>= 115), (2) Within Normal Limits (85-114), (3) Mildly Delayed Performance (70-84), and (4) Significantly Delayed Performance (\<=69). Changes from baseline are then further categorized where 'Improved' is any positive category change, 'Stable' is no category change, and 'Worsened' is any negative category change, from baseline.

    Time frame: Visit 5 (week 24)

  20. Bayley Scale of Infant Development (BSID) II Psychomotor Development Index Scores Classification Shift From Baseline at Visit 7 (Week 48) (1 Month to < 4 Year Old)

    This score is obtained from a total raw score which is the sum of a battery of individual questions. It is adjusted for a child's age, has an expected mean of 100 and standard deviation of 15, and can be categorized as: (1) Accelerated Performance (\>= 115), (2) Within Normal Limits (85-114), (3) Mildly Delayed Performance (70-84), and (4) Significantly Delayed Performance (\<=69). Changes from baseline are then further categorized where 'Improved' is any positive category change, 'Stable' is no category change, and 'Worsened' is any negative category change, from baseline.

    Time frame: Visit 7 (week 48)

07

Results

Posted Jan 13, 2010

Participant flow

102 sites in 17 countries participated in the study, of which 85 sites in 16 countries enrolled subjects in the study. First subject enrolled: 23 October 2004, Last subject last visit: 24 June 2008

Participant flow — Overall Study
MilestoneLevetiracetam
Started255
Completed180
Not completed75
Withdrew: Adverse event18
Withdrew: Lack and loss of efficacy30
Withdrew: Lost to follow-up5
Withdrew: Withdrawal by subject8
Withdrew: Protocol violation3
Withdrew: Other: mother refused to cooperate1
Withdrew: Other: given commercial drug in error2
Withdrew: Other: parents withdrew consent2
Withdrew: Other: non-compliance2
Withdrew: Other: primary care physician's decision1
Withdrew: Other: moved out of state1
Withdrew: Other: underwent surgery for epilepsy1
Withdrew: Other: sz worsening, seeking 2nd opinion1

Outcome measures

PrimaryPercentage Change (Reduction) of Partial (Type I) Seizure Frequency Per Week From Baseline Over Time During Treatment Period.

Positive changes from Baseline indicate an improvement (i.e., a reduction) in seizure frequency per week.

Time frame:
Up-titration/Conversion Period (2-8 weeks); Maintenance Period (2-8 weeks to 40-46 weeks)
Reported as:
Median · percent reduction in seizures Per Week
Percentage Change (Reduction) of Partial (Type I) Seizure Frequency Per Week From Baseline Over Time During Treatment Period.
percent reduction in seizures Per WeekLevetiracetam
Up-titration/Conversion51.06 (-10.70 to 91.59)
Maintenance68.87 (-3.60 to 96.61)
SecondaryPercentage Change (Reduction) of Total (Type I, II, III) Seizure Frequency Per Week From Baseline Over Time During Treatment Period.

Positive changes from Baseline indicate an improvement (i.e., a reduction) in seizure frequency per week.

Time frame:
Up-titration/Conversion Period (2-8 weeks); Maintenance Period (2-8 weeks to 40-46 weeks)
Reported as:
Median · Percent Reduction in Seizures per Week
Percentage Change (Reduction) of Total (Type I, II, III) Seizure Frequency Per Week From Baseline Over Time During Treatment Period.
Percent Reduction in Seizures per WeekLevetiracetam
Up-titration/Conversion Period47.44 (-21.18 to 88.70)
Maintenance Period66.02 (-3.98 to 95.00)
SecondaryPartial (Type I) Seizure Frequency Per Week Over Time During Treatment Period.
Time frame:
Up-titration/Conversion Period (2-8 weeks); Maintenance Period (2-8 weeks to 40-46 weeks)
Reported as:
Median · Seizures Per Week
Partial (Type I) Seizure Frequency Per Week Over Time During Treatment Period.
Seizures Per WeekLevetiracetam
Up-titration/Conversion Period2.85 (0.23 to 26.30)
Maintenance Period1.49 (0.07 to 17.89)
SecondaryTotal (Type I, II, III) Seizure Frequency Per Week Over Time During Treatment Period.
Time frame:
Up-titration/Conversion Period (2-8 weeks); Maintenance Period (2-8 weeks to 40-46 weeks)
Reported as:
Median · Seizures Per Week
Total (Type I, II, III) Seizure Frequency Per Week Over Time During Treatment Period.
Seizures Per WeekLevetiracetam
Up-titration/Conversion Period3.15 (0.25 to 31.17)
Maintenance Period1.91 (0.09 to 24.86)
SecondaryChange (Reduction) From Baseline in Partial (Type I) Seizure Frequency Per Week Over Time During Treatment Period

Positive changes from Baseline indicate an improvement (i.e., a reduction) in seizure frequency per week.

Time frame:
Up-titration/Conversion Period (2-8 weeks); Maintenance Period (2-8 weeks to 40-46 weeks)
Reported as:
Median · Seizures Per Week
Change (Reduction) From Baseline in Partial (Type I) Seizure Frequency Per Week Over Time During Treatment Period
Seizures Per WeekLevetiracetam
Up-titration/Conversion Period0.72 (-0.81 to 7.14)
Maintenance Period0.93 (-0.33 to 8.99)
SecondaryChange (Reduction) From Baseline in Total (Type I, II, III) Seizure Frequency Per Week Over Time During Treatment Period

Positive changes from Baseline indicate an improvement (i.e., a reduction) in seizure frequency per week.

Time frame:
Up-titration/Conversion Period (2-8 weeks); Maintenance Period (2-8 weeks to 40-46 weeks)
Reported as:
Median · Seizures Per Week
Change (Reduction) From Baseline in Total (Type I, II, III) Seizure Frequency Per Week Over Time During Treatment Period
Seizures Per WeekLevetiracetam
Up-titration/Conversion Period0.69 (-0.89 to 7.84)
Maintenance Period0.93 (-0.33 to 10.70)
SecondaryPartial Seizure (Type I) Responder Rate (Percent) During the Up-titration/Conversion Phase and by Visit During the Maintenance Phase

The responder rate is defined as the number of responders. A responder is a patient with a 50% or greater change (reduction) in partial seizure frequency per week. Note: Rates were reported as percentages.

Time frame:
Up-titration (4 weeks); Maintenance Visits 3-4 (weeks 4-14, 6-15, or 8-16); Visits 4-5 (weeks 14-24, 15-24, or 16-24); Visits 5-6 (weeks 24-36); Visits 6-7 (weeks 36-48)
Reported as:
Number · Percentage of Participants
Partial Seizure (Type I) Responder Rate (Percent) During the Up-titration/Conversion Phase and by Visit During the Maintenance Phase
Percentage of ParticipantsLevetiracetam
Up-titration/Conversion (4 weeks)50.6
Maintenance Visits 3-4 (weeks 4-14, 6-15, or 8-16)59.8
Maint. Visits 4-5 (weeks 14-24, 15-24, or 16-24);65.5
Maintenance Visits 5-6 (weeks 24-36)68.2
Maintenance Visits 6-7 (weeks 36-48)71.8
SecondaryPartial Seizure (Type I) Maximum Seizure Free Interval (Percentage of Days Belonging to a Seizure Free Interval of 28 Days or More)

For subjects with up to 24 weeks in the evaluation phase the denominator for each subject is their number of days in the evaluation phase.

Time frame:
Subjects with up to 24 weeks of exposure
Reported as:
Median · Percentage of Days
Partial Seizure (Type I) Maximum Seizure Free Interval (Percentage of Days Belonging to a Seizure Free Interval of 28 Days or More)
Percentage of DaysLevetiracetam
Partial Seizure (Type I) Maximum Seizure Free Interval (Percentage of Days Belonging to a Seizure Free Interval of 28 Days or More)0.00 (0.00 to 0.00)
SecondaryPartial Seizure (Type I) Maximum Seizure Free Interval (Percentage of Days Belonging to a Seizure Free Interval of 28 Days or More)

For subjects with greater than 24 weeks in the evaluation phase the denominator for each subject is their number of days in the evaluation phase.

Time frame:
Subjects with greater than 24 weeks of exposure
Reported as:
Median · Percentage of days
Partial Seizure (Type I) Maximum Seizure Free Interval (Percentage of Days Belonging to a Seizure Free Interval of 28 Days or More)
Percentage of daysLevetiracetam
Partial Seizure (Type I) Maximum Seizure Free Interval (Percentage of Days Belonging to a Seizure Free Interval of 28 Days or More)61.49 (0.00 to 94.07)
SecondaryTotal Seizure (Type I, II, III) Maximum Seizure Free Interval (Percentage of Days Belonging to a Seizure Free Interval of 28 Days or More)

For subjects with up to 24 weeks in the evaluation phase the denominator for each subject is their number of days in the evaluation phase.

Time frame:
Subjects with up to 24 weeks of exposure
Reported as:
Median · Percentage of Days
Total Seizure (Type I, II, III) Maximum Seizure Free Interval (Percentage of Days Belonging to a Seizure Free Interval of 28 Days or More)
Percentage of DaysLevetiracetam
Total Seizure (Type I, II, III) Maximum Seizure Free Interval (Percentage of Days Belonging to a Seizure Free Interval of 28 Days or More)0.00 (0.00 to 0.00)
SecondaryTotal Seizure (Type I, II, III) Maximum Seizure Free Interval (Percentage of Days Belonging to a Seizure Free Interval of 28 Days or More)

For subjects with greater than 24 weeks in the evaluation phase the denominator for each subject is their number of days in the evaluation phase.

Time frame:
Subjects with greater than 24 weeks of exposure
Reported as:
Median · Percentage of Days
Total Seizure (Type I, II, III) Maximum Seizure Free Interval (Percentage of Days Belonging to a Seizure Free Interval of 28 Days or More)
Percentage of DaysLevetiracetam
Total Seizure (Type I, II, III) Maximum Seizure Free Interval (Percentage of Days Belonging to a Seizure Free Interval of 28 Days or More)58.41 (0.00 to 93.81)
SecondaryTotal Seizure (Type I, II, III) Continuously Seizure Free During the Maintenance Period

The measure description is the product limit adjusted percent of subjects seizure free starting from the beginning of the Maintenance Period. The up-titration period is the up to 6 week period of increasing dose prior to the Maintenance Period. The Maintenance Period is the period of stable dosing, subsquent to the up-titration period, which could last from 42 to 48 weeks.

Time frame:
greater than or equal to 24 weeks, greater than or equal to 40 weeks
Reported as:
Number · Percentage of Participants
Total Seizure (Type I, II, III) Continuously Seizure Free During the Maintenance Period
Percentage of ParticipantsLevetiracetam
>= 24 Weeks16.5
>= 40 Weeks14.7
SecondaryPercent of Subjects With Each Seizure Type During the Evaluation Period

Type I Seizure is a partial onset Seizure (see International League Against Epilepsy definitions). Type II Seizure is a Generalized Seizure (see International League Against Epilepsy definitions). Type III Seizure is a Unknown Seizure Type (see International League Against Epilepsy definitions). A subject could experience more than one seizure type.

Time frame:
Evaluation period (48 weeks)
Reported as:
Number · Percentage of Participants
Percent of Subjects With Each Seizure Type During the Evaluation Period
Percentage of ParticipantsLevetiracetam
Type I88.6
Type II12.9
Type III7.1
SecondaryInvestigator Global Evaluation Scale

There are 7 categories, 3 for improvement (Marked improvement, Moderate improvement, Slight improvement), 3 for worsening (Slight worsening, Moderate worsening, Marked worsening), and 1 for no change (No change).

Time frame:
End of Evaluation period (week 48 or at point of early discontinuation)
Reported as:
Number · Percentage of Participants
Investigator Global Evaluation Scale
Percentage of ParticipantsLevetiracetam
Improved76.1
No Change15.3
Worsened8.6
SecondaryParent/Guardian Global Evaluation Scale

There are 7 categories, 3 for improvement (Marked improvement, Moderate improvement, Slight improvement), 3 for worsening (Slight worsening, Moderate worsening, Marked worsening), and 1 for no change (No change).

Time frame:
End of Evaluation period (week 48 or at point of early discontinuation)
Reported as:
Number · Percentage of Participants
Parent/Guardian Global Evaluation Scale
Percentage of ParticipantsLevetiracetam
Improved75.7
No Change12.6
Worsened11.7
SecondarySubject (>=8 Years Old) Global Evaluation Scale

There are 7 categories, 3 for improvement (Marked improvement, Moderate improvement, Slight improvement), 3 for worsening (Slight worsening, Moderate worsening, Marked worsening), and 1 for no change (No change).

Time frame:
End of Evaluation period (week 48 or at point of early discontinuation)
Reported as:
Number · Percentage of Participants
Subject (>=8 Years Old) Global Evaluation Scale
Percentage of ParticipantsLevetiracetam
Improved78.9
No Change15.5
Worsened5.6
SecondaryLeiter-R Associated Memory (AM) Memory Screen Composite Score Change From Baseline to Visit 5 (Week 24) and Visit 7 (Week 48) (4 to 16 Year Olds)

The Leiter-R AM battery has 10 subtests. The raw scores of the subtests are converted into scaled scores. Six composite scores are constructed from the 10 subtest scaled scores. The Memory Screen is one of them. It is composed of 2 subtests the Associated Pairs and Forward Memory. The sum of the Associated Pairs and Forward Memory subtest scaled scores are converted into a Memory composite score normally distributed with a mean and standard deviation of 100 (±15). Higher scores and positive changes from baseline are better. The range of the Memory Screen composite score is 44 to 155.

Time frame:
Baseline to Visit 5 (Week 24) and Visit 7 (Week 48)
Reported as:
Mean · Score on a scale
Leiter-R Associated Memory (AM) Memory Screen Composite Score Change From Baseline to Visit 5 (Week 24) and Visit 7 (Week 48) (4 to 16 Year Olds)
Score on a scaleLevetiracetam
Visit 5 (week 24)4.8 ± 12.6
Visit 7 (week 48)4.5 ± 15.3
SecondaryBayley Scale of Infant Development (BSID) II Mental Development Index Scores Classification Shift From Baseline at Visit 5 (Week 24) (1 Month to < 4 Year Olds)

This score is obtained from a total raw score which is the sum of a battery of individual questions. It is adjusted for a child's age, has an expected mean of 100 and standard deviation of 15, and can be categorized as: (1) Accelerated Performance (\>= 115), (2) Within Normal Limits (85-114), (3) Mildly Delayed Performance (70-84), and (4) Significantly Delayed Performance (\<=69). Changes from baseline are then further categorized where 'Improved' is any positive category change, 'Stable' is no category change, and 'Worsened' is any negative category change, from baseline.

Time frame:
Visit 5 (Week 24)
Reported as:
Number · Number of subjects
Bayley Scale of Infant Development (BSID) II Mental Development Index Scores Classification Shift From Baseline at Visit 5 (Week 24) (1 Month to < 4 Year Olds)
Number of subjectsLevetiracetam
Worsened5
Stable21
Improved4
SecondaryBayley Scale of Infant Development (BSID) II Mental Development Index Scores Classification Shift From Baseline at Visit 7 (Week 48) (1 Month to < 4 Year Olds)

This score is obtained from a total raw score which is the sum of a battery of individual questions. It is adjusted for a child's age, has an expected mean of 100 and standard deviation of 15, and can be categorized as: (1) Accelerated Performance (\>= 115), (2) Within Normal Limits (85-114), (3) Mildly Delayed Performance (70-84), and (4) Significantly Delayed Performance (\<=69). Changes from baseline are then further categorized where 'Improved' is any positive category change, 'Stable' is no category change, and 'Worsened' is any negative category change, from baseline.

Time frame:
Visit 7 (week 48)
Reported as:
Number · Number of subjects
Bayley Scale of Infant Development (BSID) II Mental Development Index Scores Classification Shift From Baseline at Visit 7 (Week 48) (1 Month to < 4 Year Olds)
Number of subjectsLevetiracetam
Worsened7
Stable17
Improved1
SecondaryBayley Scale of Infant Development (BSID) II Psychomotor Development Index Scores Classification Shift From Baseline at Visit 5 (Week 24) (1 Month to < 4 Year Old)

This score is obtained from a total raw score which is the sum of a battery of individual questions. It is adjusted for a child's age, has an expected mean of 100 and standard deviation of 15, and can be categorized as: (1) Accelerated Performance (\>= 115), (2) Within Normal Limits (85-114), (3) Mildly Delayed Performance (70-84), and (4) Significantly Delayed Performance (\<=69). Changes from baseline are then further categorized where 'Improved' is any positive category change, 'Stable' is no category change, and 'Worsened' is any negative category change, from baseline.

Time frame:
Visit 5 (week 24)
Reported as:
Number · Number of subjects
Bayley Scale of Infant Development (BSID) II Psychomotor Development Index Scores Classification Shift From Baseline at Visit 5 (Week 24) (1 Month to < 4 Year Old)
Number of subjectsLevetiracetam
Worsened1
Stable20
Improved8
SecondaryBayley Scale of Infant Development (BSID) II Psychomotor Development Index Scores Classification Shift From Baseline at Visit 7 (Week 48) (1 Month to < 4 Year Old)

This score is obtained from a total raw score which is the sum of a battery of individual questions. It is adjusted for a child's age, has an expected mean of 100 and standard deviation of 15, and can be categorized as: (1) Accelerated Performance (\>= 115), (2) Within Normal Limits (85-114), (3) Mildly Delayed Performance (70-84), and (4) Significantly Delayed Performance (\<=69). Changes from baseline are then further categorized where 'Improved' is any positive category change, 'Stable' is no category change, and 'Worsened' is any negative category change, from baseline.

Time frame:
Visit 7 (week 48)
Reported as:
Number · Number of subjects
Bayley Scale of Infant Development (BSID) II Psychomotor Development Index Scores Classification Shift From Baseline at Visit 7 (Week 48) (1 Month to < 4 Year Old)
Number of subjectsLevetiracetam
Worsened1
Stable15
Improved8

Adverse events

Collected over Up to 1 year. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Levetiracetam—46/255 (18%)206/255 (80.8%)
Most frequent serious events
Showing 10 of 44
Most frequent serious events
EventLevetiracetam
ConvulsionNervous system disorders18/255
PneumoniaInfections and infestations6/255
Status epilepticusNervous system disorders6/255
Viral infectionInfections and infestations5/255
PyrexiaGeneral disorders4/255
Upper respiratory tract infectionInfections and infestations2/255
Head injuryInjury, poisoning and procedural complications2/255
Brain oedemaNervous system disorders2/255
AspirationRespiratory, thoracic and mediastinal disorders2/255
Obstructive airways disorderRespiratory, thoracic and mediastinal disorders2/255
Most frequent other events
Showing 10 of 21
Most frequent other events
EventLevetiracetam
PyrexiaGeneral disorders81/255
Upper respiratory tract infectionInfections and infestations62/255
VomitingGastrointestinal disorders41/255
NasopharyngitisInfections and infestations38/255
DiarrhoeaGastrointestinal disorders34/255
HeadacheNervous system disorders31/255
CoughRespiratory, thoracic and mediastinal disorders29/255
IrritabilityGeneral disorders27/255
RashSkin and subcutaneous tissue disorders24/255
Otitis mediaInfections and infestations21/255

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Levetiracetam
<=18 years255
Between 18 and 65 years0
>=65 years0
Age Continuous
Age Continuous(years)Levetiracetam
Mean5.28 ± 4.69
Sex: Female, Male
Sex: Female, Male(Participants)Levetiracetam
Female116
Male139
Region of Enrollment
Region of Enrollment(participants)Levetiracetam
United States123
Russian Federation7
Italy6
United Kingdom2
India20
France7
Czech Republic9
Hungary4
Mexico6
Canada11
Poland2
Brazil29
Belgium4
Romania7
South Africa7
Germany11
08

Study locations

85 sites
  • Mobile, Alabama, United States
  • Phoenix, Arizona, United States
  • Los Angeles, California, United States
  • Denver, Colorado, United States
  • Washington, District of Columbia, United States
  • Bradenton, Florida, United States
  • Loxahatchee, Florida, United States
  • Orlando, Florida, United States
  • Pensacola, Florida, United States
  • Tallahassee, Florida, United States
  • Tampa, Florida, United States
  • Atlanta, Georgia, United States
  • Augusta, Georgia, United States
  • Chicago, Illinois, United States
  • New Orleans, Louisiana, United States
  • Boston, Massachusetts, United States
  • St. Paul, Minnesota, United States
  • Lebanon, New Hampshire, United States
  • Edison, New Jersey, United States
  • Voorhees, New Jersey, United States
  • Buffalo, New York, United States
  • New York, New York, United States
  • Rochester, New York, United States
  • Syracuse, New York, United States
  • Chapel Hill, North Carolina, United States
  • Cleveland, Ohio, United States
  • Hershey, Pennsylvania, United States
  • Philadelphia, Pennsylvania, United States
  • Charleston, South Carolina, United States
  • Germantown, Tennessee, United States
  • Nashville, Tennessee, United States
  • Fort Worth, Texas, United States
  • Galveston, Texas, United States
  • Salt Lake City, Utah, United States
  • Norfolk, Virginia, United States
  • Richmond, Virginia, United States
  • Morgantown, West Virginia, United States
  • Milwaukee, Wisconsin, United States
  • Brussels, Belgium
  • Leuven, Belgium
  • Campinas, Brazil
  • Curitiba, Brazil
  • Porto Alegre, Brazil
  • Ribeirao Preto, Brazil
  • Rio de Janeiro, Brazil
  • Sao Paulo, Brazil
  • Vancouver, British Columbia, Canada
  • Thornhill, Ontario, Canada
  • Toronto, Ontario, Canada
  • Brno, Czech Republic
  • Praha 4, Czech Republic
  • Lille Cedex, France
  • Paris, France
  • Strasbourg Cedex, France
  • Kehl, Kork, Germany
  • Berlin, Germany
  • Erlangen, Germany
  • Heidelberg, Germany
  • Jena, Germany
  • Kiel, Germany
  • Budapest, Hungary
  • Hyderabad, India
  • Lucknow, India
  • Mahim Mumbai, India
  • Mumbai, India
  • Pune Maharashtra, India
  • Calambrone, Italy
  • Genoa, Italy
  • Milano, Italy
  • Roma, Italy
  • Mexico City, Mexico
  • Gdansk, Poland
  • Bucharest, Romania
  • Cluj-Napoca, Romania
  • Tirgu-Mures, Romania
  • Kalingrad, Russian Federation
  • Moscow, Russian Federation
  • St Petersburg, Russian Federation
  • St. Petersburg, Russian Federation
  • Cape Town, South Africa
  • Capitol Park, South Africa
  • Johannesburg, South Africa
  • Bristol, United Kingdom
  • Cardiff, United Kingdom
  • London, United Kingdom
09

References and documents

Publications

  • Pina-Garza JE, Schiemann-Delgado J, Yang H, Duncan B, Hadac J, Hunter SJ. Adjunctive levetiracetam in patients aged 1 month to <4 years with partial-onset seizures: subpopulation analysis of a prospective, open-label extension study of up to 48 weeks. Clin Ther. 2010 Oct;32(11):1935-50. doi: 10.1016/j.clinthera.2010.09.017. PubMed 21095488 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2004, a primary completion of Jun 2008 and a completion of Jun 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2010, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2005
First posted
Sep 9, 2005
Start
Oct 2004
Primary completionActual
Jun 2008
CompletionActual
Jun 2008
Results first posted
Jan 13, 2010
Last update
Feb 12, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00152516
Lead sponsor
UCB Pharma
Responsible party
Sponsor
First posted
Sep 9, 2005
Start date
Oct 2004
Primary completion
Jun 2008
Completion
Jun 2008
Results posted
Jan 13, 2010
Last update
Feb 12, 2013

Study contacts

UCB Clinical Trial Call Center
study director · +1 877 822 9493

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Levetiracetam

Start the discussion